MedTrace Logo

United Kingdom (UK) Patient Preference Study of Somatuline Autogel and Treatment Administration Setting

NCT04649580 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2024-12-17

No results posted yet for this study

Summary

The aim of the study is to generate real-world evidence to describe the patient experience of administration of Somatuline® Autogel® (lanreotide) in homecare and hospital settings, and the associated impact on healthcare utilisation, societal cost, work productivity and health-related quality of life (HRQoL)

Conditions

  • Neuroendocrine Tumours (NET)

Sponsors & Collaborators

Principal Investigators

  • Ipsen Medical Director · Ipsen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-27
Primary Completion
2022-06-05
Completion
2022-06-05

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04649580 on ClinicalTrials.gov